To evaluate FTO expression in ovarian cancer, we measured mRNA and protein levels in patient‐derived ovarian cancer tissues and matched control samples, as well as in the normal ovarian epithelial cell line IOSE80 and the ovarian cancer cell line SKOV3, using RT‐PCR and western blot. This evidence concerns the gene FTO and ovarian carcinoma.